The Ultimate Cagrilintide Research Guide: Mechanism, Amylin Signaling, Clinical Research & Emerging Applications

Cagrilintide has become one of the most closely studied investigational peptides in the emerging field of amylin-based metabolic research.

Unlike GLP-1 receptor agonists, which primarily act through incretin signaling, cagrilintide is a long-acting amylin analogue designed to investigate a different biological pathway involved in appetite regulation, satiety, gastric function, and energy balance.

Interest in cagrilintide has expanded considerably as researchers have moved from early dose-finding studies into large Phase 3 programs. Cagrilintide has also been studied in combination with semaglutide as CagriSema, while more recent research has continued investigating cagrilintide as a monotherapy.

This guide examines the science behind cagrilintide, including amylin biology, receptor signaling, pharmacology, metabolic research, clinical findings, CagriSema, current development programs, and important research considerations.

What Is Cagrilintide?

Cagrilintide is a long-acting synthetic analogue of human amylin.

Amylin is a peptide hormone that is naturally produced by pancreatic β-cells and released alongside insulin following nutrient intake. The biological effects of amylin include regulation of:

• Satiety
• Food intake
• Gastric emptying
• Postprandial glucagon secretion
• Energy balance

Cagrilintide was engineered as a longer-acting analogue capable of producing sustained amylin-receptor signaling.

The FDA’s Substance Registration System identifies cagrilintide as a peptide and specifically classifies it as an amylin analogue. This makes cagrilintide particularly interesting for researchers studying the intersection of endocrine signaling, appetite regulation, and metabolic physiology.

What Is Amylin?

To understand cagrilintide, it helps to understand its endogenous counterpart: amylin.

Amylin is co-secreted with insulin by pancreatic β-cells following meals. Rather than acting simply as another blood-glucose hormone, amylin participates in the coordinated regulation of nutrient intake and post-meal physiology.

Researchers have investigated amylin signaling in relation to food intake, satiety, gastric emptying, glucagon regulation, and energy balance. The physiological system can be thought of as a coordinated feedback mechanism. After nutrient intake, multiple hormonal signals communicate with the brain and gastrointestinal system to help regulate how quickly nutrients enter circulation and how much additional food is consumed.

Cagrilintide is designed to engage this biological system for extended periods.

Cagrilintide and Amylin Receptors

One of the most interesting aspects of cagrilintide research is that amylin receptor biology is more complicated than a simple one-receptor/one-ligand system.

Amylin receptors are formed from combinations involving the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMPs). This creates several receptor complexes with distinct pharmacological properties.

Recent structural studies have provided additional insight into how cagrilintide interacts with these receptor systems. A 2025 structural study used cryo-electron microscopy to investigate cagrilintide bound to amylin and calcitonin receptor complexes. The researchers identified distinctive interactions that help explain how cagrilintide activates these receptor systems.

This is important because understanding how a peptide binds its receptor can help researchers understand downstream signaling and potentially guide development of future amylin-based compounds.

Step 1: Cagrilintide Interacts With Receptor Systems

At the molecular level, cagrilintide interacts with receptors belonging to the amylin/calcitonin receptor family. These receptors are associated with G-protein signaling, particularly pathways involving Gs proteins and intracellular cyclic AMP.

In simplified terms:

Cagrilintide → Amylin/calcitonin receptor → Gs signaling → Adenylyl cyclase → cAMP → Cellular signaling

The exact biological outcome depends on the receptor population, tissue, signaling environment, and physiological state. This is one reason receptor pharmacology is so important when studying peptide biology.

Cagrilintide and the Brain

One of the major research questions surrounding cagrilintide is where its effects on appetite and body weight originate.

Research suggests that amylin-related signaling involves neural circuits responsible for integrating information about nutrient availability and satiety. The hindbrain is particularly important.

Recent preclinical research examining cagrilintide found evidence supporting involvement of AMY1R and AMY3R in its effects on body weight. In mouse models, disruption of RAMP1 and RAMP3 altered cagrilintide’s effects, providing additional evidence that these receptor complexes contribute to its pharmacology.

Cagrilintide and Food Intake

One of the most extensively investigated effects of amylin signaling is regulation of food intake. Amylin-related signaling can contribute to satiety, helping communicate that sufficient nutrients have been consumed.

Preclinical research has observed reductions in food intake following cagrilintide exposure, with effects involving brain regions associated with feeding regulation. This makes cagrilintide particularly interesting to researchers studying appetite regulation, satiety signaling, energy balance, neural control of feeding, obesity physiology, and gut-brain communication.

Cagrilintide and Gastric Emptying

Another important component of amylin physiology is its influence on gastric emptying. The rate at which food leaves the stomach influences how rapidly nutrients enter the small intestine and circulation.

Slower gastric emptying can alter post-meal glucose excursions, satiety signaling, nutrient absorption dynamics, and hunger between meals. Because gastric physiology interacts closely with neural and hormonal signaling, researchers study this mechanism as part of the broader effects of amylin analogues.

Cagrilintide and Energy Balance

Body weight is ultimately influenced by a complex network of factors involving energy intake and energy expenditure. Cagrilintide’s primary research interest lies heavily in the regulation of energy intake and satiety, rather than functioning as a direct stimulant of energy expenditure.

This is an important distinction when comparing cagrilintide with compounds that act through other metabolic pathways. For example, amylin signaling primarily influences appetite/satiety, gastric physiology, and nutrient regulation, whereas other pathways may emphasize incretin signaling (GLP-1), energy expenditure (glucagon), or nutrient sensing (GIP).

This difference is one reason combination strategies have become such an important area of research.

Cagrilintide vs. GLP-1 Signaling

Because the mechanisms aren’t identical, researchers became interested in whether the two pathways could produce complementary effects. That question ultimately led to the development of CagriSema.

What Is CagriSema?

CagriSema is the combination of cagrilintide + semaglutide.

The concept is based on combining two distinct biological mechanisms:

• Cagrilintide — Amylin analogue
• Semaglutide — GLP-1 receptor agonist

The idea is that complementary signaling pathways may produce greater effects on energy intake and body weight than either pathway alone. This combination has now progressed through major Phase 3 studies.

REDEFINE 1: Major Phase 3 Research

One of the most important studies in cagrilintide’s development is REDEFINE 1.

The Phase 3a trial enrolled adults with obesity or overweight accompanied by an obesity-related complication and compared CagriSema with placebo and the individual components. The trial lasted 68 weeks.

The published New England Journal of Medicine results reported an estimated mean body-weight change of −20.4% with CagriSema versus −3.0% with placebo under the treatment-policy estimand used in the publication. Participants receiving CagriSema were more likely to achieve larger weight-loss thresholds.

Gastrointestinal adverse events were common (nausea, vomiting, diarrhea, constipation, and abdominal pain) and were generally described as transient and mild-to-moderate in the trial population.

Why REDEFINE 1 Matters

The significance of REDEFINE 1 isn’t simply the magnitude of weight change. The trial provided large-scale clinical evidence that amylin and GLP-1 biology can be combined into a single therapeutic strategy.

ClinicalTrials.gov lists REDEFINE 1 as a Phase 3 study sponsored by Novo Nordisk (NCT05567796).

Cagrilintide and Type 2 Diabetes Research

Cagrilintide-containing combinations have also been investigated in people with type 2 diabetes.

In the Phase 3 REDEFINE 2 trial, CagriSema produced a greater reduction in body weight than placebo over 68 weeks. The published results reported −13.7% versus −3.4% with placebo under the treatment-policy estimand. The study also reported improvements in glycemic measures, including the proportion of participants reaching an HbA1c of 6.5% or lower.

These findings are important because they allow researchers to examine the interaction between amylin signaling, GLP-1 signaling, body weight, and glucose metabolism in a population with established metabolic disease.

Cagrilintide as a Standalone Research Compound

Although much of the public attention has focused on CagriSema, cagrilintide itself has also been studied independently.

The original Phase 2 dose-finding trial investigated once-weekly cagrilintide in adults with overweight or obesity. The study was randomized, double-blind, placebo-controlled and active-controlled.

More recent analysis of Phase 3 data has further strengthened interest in cagrilintide monotherapy. Novo Nordisk reported that a Phase 3 REDEFINE 1 sub-analysis found once-weekly cagrilintide at 2.4 mg produced an average 11.8% body-weight reduction versus 2.3% with placebo after 68 weeks under an efficacy estimand. The company subsequently advanced cagrilintide into the Phase 3 RENEW program.

This is an important development because it separates the scientific question of what amylin signaling can accomplish by itself from what happens when amylin signaling is combined with GLP-1 signaling.

Why Researchers Are Interested in Cagrilintide Monotherapy

Studying cagrilintide independently allows researchers to investigate the specific contribution of amylin signaling. This can help answer questions involving satiety, food intake, body-weight regulation, amylin receptor pharmacology, neural signaling, gastric physiology, combination therapy, and metabolic adaptation.

It also provides a useful experimental comparator when investigating multi-pathway metabolic therapies.

New Structural Research: Understanding Cagrilintide at the Receptor

One of the most interesting developments in the cagrilintide literature has been the emergence of detailed structural studies.

Recent cryo-EM research examined cagrilintide bound to multiple receptor complexes, including AMY1R, AMY2R, AMY3R, and the calcitonin receptor. The researchers found that cagrilintide interacts with these receptors through distinctive binding configurations and activates Gs-associated signaling.

This type of research goes beyond simply asking “Does cagrilintide work?” Instead, researchers can begin asking “Exactly how does the molecule interact with its receptor?” That distinction is fundamental to modern molecular pharmacology.

Cagrilintide and the Gut-Brain Axis

Another important research area involves the gut-brain axis. Appetite isn’t controlled by a single brain region. Instead, information from the gastrointestinal tract, pancreas, adipose tissue, circulating hormones, and nutrient availability is integrated through peripheral and central nervous-system pathways.

Amylin is one component of this network. Cagrilintide therefore provides researchers with a useful tool for investigating how peripheral hormonal signals influence central feeding circuits.

Why Combination Therapies Are So Interesting

One of the biggest themes emerging from metabolic research is that obesity is multifactorial. A single signaling pathway may influence several physiological processes, but multiple pathways can potentially interact.

Researchers are therefore studying combinations involving amylin, GLP-1, and other emerging metabolic targets. The rationale is not simply “more signaling.” The objective is to understand whether complementary mechanisms can address different components of energy regulation.

CagriSema is one of the most advanced examples of this research strategy.

Important Research Considerations

Cagrilintide research should always be interpreted within the context of study design. Important variables include species, dose, duration, route of administration, receptor expression, baseline metabolic state, diet, sex, age, concurrent treatments, and study endpoints.

Results observed in an animal model cannot automatically be extrapolated to humans. Likewise, results from a combination of cagrilintide and semaglutide should not automatically be attributed entirely to cagrilintide. This distinction is especially important when interpreting CagriSema studies.

Current Development Landscape

Cagrilintide is no longer an early-stage experimental concept. It has progressed from Phase 2 dose-finding research into large-scale Phase 3 development.

ClinicalTrials.gov currently lists REDEFINE 1 as a Phase 3 study (NCT05567796). Novo Nordisk has also advanced cagrilintide monotherapy into the RENEW Phase 3 program. Meanwhile, CagriSema has progressed through multiple Phase 3 studies.

Novo Nordisk submitted CagriSema to the FDA in December 2025, with a regulatory decision anticipated in the fourth quarter of 2026 according to the company’s current reporting. That regulatory status should be distinguished from cagrilintide itself — cagrilintide remains an investigational compound.

Frequently Asked Questions

Related Reading on Summit Pep Labs

• Ultimate Retatrutide Research Guide
• Tesamorelin Research Guide
• KLOW Peptide Research Guide
• What Does 99% HPLC Purity Mean? A Complete Guide to Research Peptide Quality
• Peptide Storage & Handling Guide

Researchers evaluating experimental peptide materials should also understand how HPLC, LC-MS and batch-specific COAs are used to characterize research compounds.

Researchers evaluating experimental peptide materials should also understand how HPLC, LC-MS and batch-specific COAs are used to characterize research compounds.

External Research References

• Once-weekly cagrilintide for weight management – Phase 2 trial (PubMed / Lancet)
• REDEFINE 1 – Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (NEJM)
• REDEFINE 2 – Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (NEJM)
• ClinicalTrials.gov – REDEFINE 1 (NCT05567796)
• Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors (Nature Communications)
• Structural and dynamic features of cagrilintide binding (PubMed)
• Structural and mechanistic insights into dual activation of cagrilintide (PubMed)

Final Thoughts

Cagrilintide represents an important development in the study of amylin-based metabolic signaling.

Unlike GLP-1 receptor agonists, cagrilintide works through the amylin/calcitonin receptor system, providing researchers with a different biological mechanism for investigating appetite, satiety, gastric physiology and energy balance.

The research landscape has also evolved substantially. Early Phase 2 studies established the basis for investigating once-weekly cagrilintide. Large Phase 3 studies subsequently provided clinical evidence for the combination of cagrilintide and semaglutide, while newer work has continued examining cagrilintide as a standalone compound and exploring the molecular details of its receptor interactions.

Perhaps most importantly, modern structural studies are beginning to explain why cagrilintide interacts with its receptor targets the way it does. That combination of clinical, pharmacological and structural research makes cagrilintide an especially interesting molecule for researchers studying the future of metabolic biology.